Zero Point Five Therapeutics, Inc., also known as ZP5 Therapeutics, is a biotechnology company focused on developing effective treatments for neglected tropical diseases, particularly soil-transmitted helminthiasis (STH). The company aims to create accessible therapies for diseases that disproportionately affect marginalized communities worldwide, addressing a critical health crisis caused by intestinal parasitic infections.
ZP5-9676 is a drug candidate based on flubendazole and is currently in Phase 3 clinical trials, aimed at treating infections caused by soil-transmitted helminths including hookworm, roundworm, and whipworm.
ZP5-9676 addresses the crucial gap in effective treatments for STH infections in low-resource settings, aiming to reduce the burden of parasitic diseases and improve health outcomes.
The lack of effective, accessible treatments for NTDs, high prevalence of malnutrition and growth issues related to parasitic infections, and significant health disparities in low-income populations.